Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 574

1.

NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis.

Hicks T, Stewart F, Eisinga A.

Open Heart. 2016 Jan 18;3(1):e000279. doi: 10.1136/openhrt-2015-000279. eCollection 2016.

2.

Asian strategy for stroke prevention in atrial fibrillation.

Chiang CE, Wang KL, Lin SJ.

Europace. 2015 Oct;17 Suppl 2:ii31-ii39. doi: 10.1093/europace/euv231. Review.

PMID:
26842113
3.

[Management of bleeding complications associated with NOAC].

von Ameln-Mayerhofer A.

Med Monatsschr Pharm. 2015 Oct;38(10):389-93. German.

PMID:
26731856
4.
5.

Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.

Sarma A, Giugliano RP.

Hosp Pract (1995). 2015 Dec;43(5):258-67. doi: 10.1080/21548331.2015.1103190. Epub 2015 Nov 11.

PMID:
26559852
6.

[Novel oral anticoagulants (NOAC)].

Ieko M.

Rinsho Ketsueki. 2015 Oct;56(10):2123-33. doi: 10.11406/rinketsu.56.2123. Japanese.

PMID:
26458452
7.

TO BLEED OR NOT TO BLEED: THAT IS THE QUESTION. THE SIDE EFFECTS OF APIXABAN.

Ciccone MM, Zito A, Devito F, Maiello M, Palmiero P.

Curr Drug Targets. 2015 Oct 1. [Epub ahead of print]

PMID:
26424386
8.

Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation.

Kaiser K, Cheng WY, Jensen S, Clayman ML, Thappa A, Schwiep F, Chawla A, Goldberger JJ, Col N, Schein J.

Curr Med Res Opin. 2015 Dec;31(12):2261-72. doi: 10.1185/03007995.2015.1096767. Epub 2015 Oct 22.

PMID:
26390360
9.

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).

Bansilal S, Bloomgarden Z, Halperin JL, Hellkamp AS, Lokhnygina Y, Patel MR, Becker RC, Breithardt G, Hacke W, Hankey GJ, Nessel CC, Singer DE, Berkowitz SD, Piccini JP, Mahaffey KW, Fox KA; ROCKET AF Steering Committee and Investigators.

Am Heart J. 2015 Oct;170(4):675-682.e8. doi: 10.1016/j.ahj.2015.07.006. Epub 2015 Jul 17.

10.

Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care.

Guimarães PO, Kaatz S, Lopes RD.

Int J Gen Med. 2015 Sep 7;8:283-91. doi: 10.2147/IJGM.S62760. eCollection 2015. Review.

11.

Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.

Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M.

J Thromb Haemost. 2015 Nov;13(11):2012-20. doi: 10.1111/jth.13139. Epub 2015 Oct 5.

PMID:
26356595
12.

Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation.

Eckman MH.

J Thromb Thrombolysis. 2016 Feb;41(2):234-40. doi: 10.1007/s11239-015-1276-5.

PMID:
26343041
13.

Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.

van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, Schutgens RE, Klijn CJ; APACHE-AF Investigators.

Trials. 2015 Sep 4;16:393. doi: 10.1186/s13063-015-0898-4.

14.

Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.

Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY.

Eur J Heart Fail. 2015 Nov;17(11):1192-200. doi: 10.1002/ejhf.343. Epub 2015 Sep 3.

PMID:
26335355
15.

The evolving role of dabigatran etexilate in clinical practice.

Hellenbart E, Drambarean B, Lee J, Nutescu EA.

Expert Opin Pharmacother. 2015;16(13):2053-72. Epub 2015 Aug 6.

PMID:
26245513
16.

[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].

Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, Bagheri H.

Therapie. 2015 Nov-Dec;70(6):485-92. doi: 10.2515/therapie/2015032. Epub 2015 Jul 29. French.

PMID:
26223162
17.

Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.

Maura G, Blotière PO, Bouillon K, Billionnet C, Ricordeau P, Alla F, Zureik M.

Circulation. 2015 Sep 29;132(13):1252-60. doi: 10.1161/CIRCULATIONAHA.115.015710. Epub 2015 Jul 21.

PMID:
26199338
18.

Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke.

Yaghi S, Kamel H, Elkind MS.

Neurology. 2015 Sep 22;85(12):1078-84. doi: 10.1212/WNL.0000000000001817. Epub 2015 Jul 17. Review.

PMID:
26187229
19.

Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.

Arbit B, Hsu JC.

Clin Cardiol. 2015 Nov;38(11):684-91. doi: 10.1002/clc.22434. Epub 2015 Jul 14. Review.

20.

Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.

Potpara TS, Lip GY.

Prog Cardiovasc Dis. 2015 Sep-Oct;58(2):177-94. doi: 10.1016/j.pcad.2015.07.003. Epub 2015 Jul 7. Review.

PMID:
26162958
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk